Business Context and Reporting Period
Company: Matinas BioPharma Holdings, Inc. (MTNB)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: A clinical-stage biopharmaceutical company focused on its lipid nanocrystal (LNC) platform delivery technology. The lead product candidate is MAT2203. The company is currently in a "going concern" status, with substantial doubt regarding its ability to continue operations without additional financing or strategic partnerships.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(1,921,000) | $(1,656,000) |
| Net Loss Per Share (Basic & Diluted) | $(0.30) | $(0.33) |
| Research & Development Expenses | $0 | $85,000 |
| General & Administrative Expenses | $1,936,000 | $1,861,000 |
| Cash and Cash Equivalents (End of Period) | $2,398,000 | $6,924,000 |
| Restricted Cash | $250,000 | $250,000 |
| Total Stockholders' Equity | $3,022,000 | $6,270,000 |
| Accumulated Deficit | $(212,708,000) | $(201,480,000) |
Liquidity: The company reported a net cash used in operating activities of $1.601 million for Q1 2026. Management states that existing cash is insufficient to fund operations for the next 12 months.
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses decreased slightly to $1.936 million from $1.946 million in Q1 2025. This was driven by a complete cessation of R&D expenses ($0 vs. $85,000) due to a pause in the MAT2203 development program and headcount reductions. However, G&A expenses increased by $75,000 due to higher legal and consulting fees.
- Warrant Liability: In Q1 2025, the company recognized a $294,000 gain from the change in fair value of warrant liabilities. No such liability or gain existed in Q1 2026.
- Cash Position: Cash and cash equivalents declined significantly from $6.924 million in Q1 2025 to $2.398 million in Q1 2026, reflecting continued operating losses and no financing inflows in the current quarter.
- Stockholders' Equity: Equity decreased from $6.27 million in Q1 2025 to $3.022 million in Q1 2026, primarily due to the net loss for the period.
Outlook, Risks, and Contingencies
- Going Concern: The filing explicitly states substantial doubt exists regarding the company's ability to continue as a going concern. Survival depends on securing partners for MAT2203, controlling expenses, or raising additional capital via equity offerings or the At-The-Market (ATM) Sales Agreement.
- Listing Compliance Risk: On April 2, 2026, the company received notice from NYSE American regarding non-compliance with stockholders' equity requirements (minimum $6.0 million for companies with losses in five of the last five fiscal years). The company has submitted a plan to regain compliance but faces potential delisting if the plan is not accepted or compliance is not achieved within the cure period.
- Legal Proceedings: A dispute with the landlord of the Bridgewater, NJ facility regarding an alleged illegal lockout was resolved via a settlement agreement effective April 7, 2026. The company paid a termination fee of $765,000 (partially satisfied by a security deposit) and vacated the premises on April 29, 2026.
- Strategic Focus: Management is prioritizing the monetization of MAT2203 through licensing or sale to a partner to fund Phase 3 trials, rather than self-funding development.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $2.398 million cash balance against the stated inability to fund operations for 12 months.
- NYSE Compliance: Monitor the status of the company's plan to regain compliance with NYSE American stockholders' equity requirements to assess delisting risk.
- Partnership Progress: Track any announcements regarding the licensing or sale of MAT2203, which is critical for future funding.
- ATM Capacity: Review the remaining capacity under the At-The-Market Sales Agreement ($44.191 million) and any restrictions based on public float.
- Subsequent Events: Confirm the financial impact of the $765,000 lease termination payment made in April 2026 on the upcoming quarter's cash flow.